Organization
CNBG-Virogin Biotech (Shanghai)
5 clinical trials
Clinical trial
A Dose Ascending, Open Phase Ib/IIa Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Efficacy of VG161 Combined With Nivolumab Injection in Subjects With Metastatic Gastric CancerStatus: Recruiting, Estimated PCD: 2025-12-01
Clinical trial
A Single-arm, Multicenter, Open-label Phase IIa Clinical Study to Evaluate the Efficacy and Safety of VG161 in the Treatment of Advanced Bone and Soft Tissue SarcomaStatus: Recruiting, Estimated PCD: 2025-07-17
Clinical trial
A Randomized, Blinded, Controlled Phase II Clinical Trial to Evaluate the Immunogenicity and Safety of a COVID-19 mRNA Vaccine (ZSVG-02-O) in a Healthy Population 18 Years of Age and OlderStatus: Recruiting, Estimated PCD: 2023-10-30
Clinical trial
An Open-label Phase Ib/IIa Clinical Trial of VG161 Combined With Camrelizumab in the Treatment of Advanced Primary Hepatocellular CarcinomaStatus: Not yet recruiting, Estimated PCD: 2025-12-30
Clinical trial
A Randomised, Blinded, Parallel-controlled Phase 1 Clinical Trial to Evaluate the Safety and Preliminary Immunogenicity of a COVID-19 mRNA Vaccine in Healthy Adult SubjectsStatus: Recruiting, Estimated PCD: 2023-06-30